Roche's Alecensa notches trial win against Pfizer's Xalkori

ZURICH (Reuters) - Roche's Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Pfizer's Xalkori, the Swiss drugmaker said on Monday, as it seeks to move in on the U.S. company's share of early treatment of the disease.